Vaccine stock should be able t_老虎社区_美港股上老虎

VJerome
2021-07-16

Vaccine stock should be able to upkeep for sometime

Moderna Surges to Record High as Vaccine Maker Added to S&P 500

Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t

Moderna Surges to Record High as Vaccine Maker Added to S&P 500

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":170469154,"tweetId":"170469154","gmtCreate":1626446170978,"gmtModify":1631890808159,"author":{"id":3572917288001192,"idStr":"3572917288001192","authorId":3572917288001192,"authorIdStr":"3572917288001192","name":"VJerome","avatar":"https://static.tigerbbs.com/52e715ad2cbd0da71c65fb18fe9e41a4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Vaccine stock should be able to upkeep for sometime&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Vaccine stock should be able to upkeep for sometime&nbsp;</p></body></html>","text":"Vaccine stock should be able to upkeep for sometime","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/170469154","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","pubTimestamp":1626445586,"share":"https://www.laohu8.com/m/news/1168174427?lang=&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc.&nbsp;(<b>MRNA</b>)&nbsp;shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&amp;P 500 benchmark next week.</p>\n<p>Moderna will replaceAlexion Pharmaceuticals&nbsp;(<b>ALXN</b>) &nbsp;in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca&nbsp;(<b>AZN</b>)&nbsp;in December of last year.</p>\n<p>Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p>\n<p>Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p>\n<p>Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p>\n<p>\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p>\n<p>Last month, the groupformally asked the U.S. Food &amp; Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p>\n<p>Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p>\n<p>The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-16 22:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500><strong>Thestreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the ...</p>\n\n<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","ALXN":"亚力兄制药","MRNA":"Moderna, Inc."},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN)  in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1},"isVote":1,"tweetType":1,"viewCount":345,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":43,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}

Moderna Surges to Record High as Vaccine Maker Added to S&P 500

评论（1）

热议股票